TERRAMYCIN W/ POLYMYXIN Drug Patent Profile

Which patents cover Terramycin W/ Polymyxin, and what generic alternatives are available?

Terramycin W/ Polymyxin is a drug marketed by Pfizer and Casper Pharma Llc and is included in two NDAs.

The generic ingredient in TERRAMYCIN W/ POLYMYXIN is oxytetracycline hydrochloride; polymyxin b sulfate. There are thirty-six drug master file entries for this compound. Additional details are available on the oxytetracycline hydrochloride; polymyxin b sulfate profile page.

Summary for TERRAMYCIN W/ POLYMYXIN

US Patents:	0
Applicants:	2
NDAs:	2
DailyMed Link:	TERRAMYCIN W/ POLYMYXIN at DailyMed

US Patents and Regulatory Information for TERRAMYCIN W/ POLYMYXIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	TERRAMYCIN W/ POLYMYXIN	oxytetracycline hydrochloride; polymyxin b sulfate	OINTMENT;OTIC	061841-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Casper Pharma Llc	TERRAMYCIN W/ POLYMYXIN B SULFATE	oxytetracycline hydrochloride; polymyxin b sulfate	OINTMENT;OPHTHALMIC	061015-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Last updated: July 30, 2026

TERRAMYCIN W/ POLYMYXIN market dynamics and financial trajectory (sales, competition, and exclusivity risks)

Executive summary: Terramycin with Polymyxin is an older, off-patent combination antibiotic product in the US that has shifted into a generic, multi-manufacturer market with limited pricing power. Its financial trajectory is driven less by exclusivity and more by (1) the breadth of generic substitution across labeling strengths and dosage forms, (2) channel consolidation in retail and institutional procurement, (3) periodic supply continuity events, and (4) competition from newer ophthalmic and topical antibiotic classes. For new entrants, the dominant regulatory pathway is Abbreviated New Drug Application (ANDA) and labeling alignment, with the main barrier typically being formulation/manufacturing continuity rather than patent life.

What is the market size and revenue trajectory for Terramycin w/ Polymyxin in the US?

Featured answer: Public financial visibility for “Terramycin w/ Polymyxin” is usually constrained because it is marketed as a branded combination within a segment dominated by generics. Revenue trends typically follow broader antibiotic topical/ophthalmic category patterns: stable demand, price erosion after generic entry, and intermittent substitution-driven volume swings.

How does demand behave for topical/ophthalmic antibiotic combinations?

• Demand is episodic and clinician driven, with volume tied to infection incidence (conjunctivitis, secondary bacterial infection in minor ocular surface disease, or skin surface bacterial infections depending on the exact product labeling).
• Substitution dynamics are fast when equivalent generics are available on contract formularies.
• Patient and prescriber switching occurs when:
  • acquisition costs change materially,
  • supply constraints disrupt branded availability,
  • therapeutic equivalence is confirmed in procurement and practice.

What typically drives annual sales volatility?

• Contract pharmacy and hospital group purchasing organization (GPO) rebids.
• Inventory positioning ahead of shortages.
• Product supply disruptions in specific NDCs or pack sizes.

What patents and exclusivity protect Terramycin with Polymyxin, and when do they expire?

Featured answer: For Terramycin with Polymyxin, the practical exclusivity ceiling is typically already reached for US innovator and formulation innovation due to product age. Any remaining patent value would usually be limited to specific NDC-level formulation/manufacturing or method-of-use claims, but these generally do not sustain brand economics once multiple ANDA products are established.

How to evaluate remaining IP risk in practice

Even for older combination antibiotics, teams typically check:

• Orange Book listing status per NDC and strength
• whether any “use” patents attach to specific labeling indications
• whether any process patents exist that block ANDA manufacturing routes
• whether patent litigation or settlements exist that delay generic launch

What exclusivity typically matters for older products

• New Chemical Entity (NCE) exclusivity is not applicable given the age of tetracycline derivatives (Terramycin is oxytetracycline) and polymyxins in US development history.
• Orphan drug exclusivity is unlikely for routine bacterial infections treated with topical antibiotics.
• Any exclusivity still relevant would be tied to specific formulation approvals or pediatric exclusivity, but those would also be time-limited and typically listed in the Orange Book for the exact NDC.

What is the Orange Book status of Terramycin with Polymyxin, and are generics approved for the same indications?

Featured answer: The Orange Book status for Terramycin with Polymyxin generally reflects a mature generic environment where multiple ANDAs exist or could exist for labeled strengths and dosage forms. Practical consequence: brand pricing power is constrained, and generics can substitute without waiting for brand exclusivity.

How to map the competitive ANDA set

For market access and litigation exposure, the market teams should map:

• NDC-level generic presence for each strength/pack configuration
• application status (approved ANDA vs pending ANDA)
• labeling equivalence and bioequivalence requirements for topical products

Which companies compete with Terramycin w/ Polymyxin, and how does the competitive landscape affect pricing?

Featured answer: Competition is usually from established generic manufacturers with negotiated hospital and retail contracts. This compresses net pricing for the brand and shifts market share toward lower-cost supply leaders.

Competitive mechanics in older antibiotic markets

• WAC-to-net price compression after generic entry.
• Formulary tiering based on contract pricing.
• Tender-based switching for institutional procurement.

Pricing outcomes typically observed

• Brand pricing approaches generic parity or is replaced on contracts.
• Remaining branded sales often come from:
  • inventory residuals,
  • clinician preference where generics are out of stock,
  • specific pack size or distribution routes.

How does Terramycin w/ Polymyxin compare with other topical antibiotic options (bacitracin, erythromycin, fluoroquinolones)?

Featured answer: Relative performance is mainly about spectrum, tolerability, and clinician comfort, with fluoroquinolone ophthalmics generally capturing share for broader coverage, while older tetracycline/polymyxin combinations compete in narrower or cost-sensitive segments.

Class-level comparison that affects sales

• Terramycin (oxytetracycline) plus polymyxin targets bacterial strains covered by tetracyclines and polymyxins, with the combination used historically for mixed bacterial coverage.
• Newer ophthalmic fluoroquinolones often win when clinicians seek broader Gram-negative and faster convenience dosing patterns, where clinically appropriate.

Net effect on financial trajectory

• Category share shifts away from older antibiotic combinations as newer options become default in many prescribing guidelines and formularies.
• For many markets, remaining branded demand is mostly a mix of substitution inertia plus contract-driven pricing.

When does generic entry risk peak for Terramycin with Polymyxin, and what triggers it?

Featured answer: In mature products, peak generic risk is not tied to a single date, but to ongoing ANDA supply expansions and contract rebids. Even without active Paragraph IV events, new generic entrants can still erode remaining brand share.

Triggers that change the sales curve

• ANDA approvals that add new manufacturers or NDC pack formats.
• Volume loss from GPO switchouts.
• National drug shortage events ending for a specific competitor, rebalancing supply and prices.
• Labeling changes that alter formulary eligibility.

What patent litigation, settlements, or Paragraph IV challenges affect Terramycin with Polymyxin?

Featured answer: For older products with established generic availability, Paragraph IV litigation (if it occurred) usually happened around first-wave generic entries. Current financial exposure would be limited unless a later-wave NDA/ANDA introduced new formulations or a new manufacturing route required court-ordered exclusivity.

Litigation-driven market events that would matter

• Settlement that delays a follow-on ANDA launch by months or years.
• Court decisions narrowing claim scope, enabling earlier generic approval.
• Stays that impact specific NDCs rather than the entire drug product line.

What formulation and manufacturing/IP barriers matter for generic applicants?

Featured answer: For topical antibiotic combinations, barriers tend to be formulation stability, process controls, and meeting labeling-specific standards. Once a generic is established, the remaining risks are quality and supply continuity rather than patentability.

Where generic risk concentrates

• Sterility or preservative system alignment (if ophthalmic and labeling requires it).
• Particle/vehicle consistency for ocular products.
• Packaging compatibility and shelf-life validation.
• Batch release criteria.

How does FDA status influence market access for Terramycin with Polymyxin?

Featured answer: FDA status impacts availability more than exclusivity. For mature antibiotics, the key issue is whether each NDC is actively marketed, stable in distribution, and compliant with current labeling and quality requirements.

Regulatory pathway typical for generics

• ANDA with Paragraph III or bioequivalence approach appropriate for topical products.
• Labeling equivalence to brand.
• Updated cGMP and stability packages.

What does the financial trajectory look like across the product lifecycle?

Featured answer: The life-cycle pattern for older branded antibiotic combinations is: strong early revenue, rapid price compression after generic entry, a plateau at reduced net revenue, and further declines when newer classes and preferred formularies take share.

Lifecycle curve segmentation

1. Brand build phase: higher unit pricing, limited generic presence.
2. Generic substitution phase: accelerated net revenue decline as contracts switch.
3. Mature plateau: low brand margin, stable unit demand.
4. Downward drift: category share shift to newer antibiotics; limited upside absent supply shocks benefiting the brand.

Which business risks and opportunities most affect investors and acquirers?

Featured answer: The main business risks are net price compression, channel substitution, and supply volatility. Opportunities tend to be narrow and event-driven, such as securing manufacturing capacity, maintaining reliable distribution, or winning institutional contracts where the brand remains stocked.

Risk map

• Revenue: continued generic-led pricing erosion.
• Volume: formulary tier changes and GPO switches.
• Operations: manufacturing continuity for combination products is operationally heavier than single agents.
• Compliance: topical/ophthalmic quality expectations.

Opportunity map

• Strategic contracting for NDC-level supply continuity.
• Contracting in cost-sensitive segments where older combinations remain acceptable.
• Bundling or package optimization for institutional purchasing.

Key Takeaways

• Terramycin with Polymyxin operates in a mature, generic-constrained market where net revenue is mainly shaped by contract pricing, formulary substitution, and supply continuity rather than by brand exclusivity.
• Financial trajectory typically shows post-generic price compression followed by a plateau and gradual decline as newer antibiotic classes take preferred share.
• Competitive advantage, where any exists, comes from reliable manufacturing and distribution and winning or retaining contracts, not from patent-driven insulation.
• Ongoing ANDA competition and NDC-specific supply shifts pose ongoing generic entry pressure even when headline exclusivity has long passed.

FAQs

1. Is Terramycin w/ Polymyxin considered interchangeable with ophthalmic fluoroquinolone antibiotics on formularies?
2. How do hospital GPO contract cycles typically impact brand vs generic uptake for topical antibiotic NDCs?
3. What NDC-level factors most often drive supply-related revenue spikes or drops for mature combination antibiotics?
4. Do combination topical antibiotics face more generic substitution barriers than single-ingredient products?
5. What labeling or manufacturing changes most commonly trigger ANDA rework or market delays for older topical antibiotics?

References

1. FDA, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-07-30).
2. FDA. Application Integrity Policy and ANDA framework for generic drug approvals. U.S. Food and Drug Administration. https://www.fda.gov/ (accessed 2026-07-30).